OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
9201
Results
Show all
Save search
Copy query
Show results for
Unknown
(6936)
Genomics
(1130)
Transcriptomics
(808)
Proteomics
(205)
Other
(54)
Metabolomics
(28)
Models
(14)
Methylation profiling
(13)
Clinical
(9)
Genomic
(3)
Multiomics
(2)
Organisms
Homo sapiens
(653)
Mus musculus
(497)
Allexis
(126)
Arabidopsis thaliana
(126)
Callinectes sapidus
(126)
Drosophila
(126)
Drosophila melanogaster
(126)
Ensifer adhaerens
(126)
Entamoeba histolytica
(126)
Escherichia coli
(126)
Leishmania major strain Friedlin
(126)
Listeria monocytogenes
(126)
Medicago truncatula
(126)
Methylohalobius crimeensis 10Ki
(126)
Mus musculus
(126)
Mycobacterium tuberculosis
(126)
Oryza sativa Indica Group
(126)
Physcomitrium patens
(126)
Macaca mulatta
(3)
Danio rerio
(3)
human gut metagenome
(1)
Mesocricetus auratus
(1)
synthetic virus
(1)
unidentified plasmid
(1)
Severe acute respiratory syndrome coronavirus 2
(1)
Canis lupus
(1)
unidentified
(1)
Canis lupus familiaris
(1)
African swine fever virus
(1)
Rattus rattus
(1)
Organisms
Mus musculus
(393)
Homo sapiens
(363)
Macaca mulatta
(3)
Danio rerio
(3)
human gut metagenome
(2)
Canis lupus
(1)
Mus musculus musculus
(1)
mouse metagenome
(1)
Cryptosporidium parvum
(1)
unidentified
(1)
Repository
ENA
(911)
geo
(744)
biostudies-arrayexpress
(205)
EGA
(148)
pride
(126)
MassIVE
(41)
MetaboLights
(28)
iProX
(22)
BioModels
(14)
jPOST
(8)
PanoramaPublic
(4)
dbGaP
(3)
EVA
(2)
Tissue
Cell culture
(30)
Blood
(18)
T cell
(16)
B cell
(13)
Cell suspension culture
(8)
Lung
(8)
Dendritic cell
(7)
Epithelial cell
(6)
Melanocyte
(6)
Permanent cell line cell
(6)
Skin
(6)
Spleen
(6)
Bone marrow
(5)
Brain
(5)
Macrophage
(5)
Primary cell
(4)
Colon
(3)
Kidney
(3)
Leukocyte
(3)
Liver
(3)
Monocyte
(3)
Stem cell
(3)
Blood cell
(2)
Cerebellum
(2)
Cerebrospinal fluid
(2)
Cytotoxic T-lymphocyte
(2)
Fibroblast
(2)
Heart
(2)
Lymph node
(2)
Ovary
(2)
Disease
Melanoma
(7)
Acute leukemia
(5)
Lymphoma
(5)
Brain cancer
(4)
Lung cancer
(4)
Malignant neoplasm of ovary
(4)
Carcinoma
(3)
Colorectal Neoplasms
(3)
Colon cancer
(3)
Disease free
(3)
Multiple myeloma
(3)
Lymphoid leukemia
(2)
Neoplasms
(2)
Alzheimer's disease
(2)
Breast cancer
(2)
Chronic lymphocytic leukemia
(2)
Skin melanoma
(2)
Tumor bearing
(1)
Ewing family tumor
(1)
Monoclonal gammopathy of undetermined significance (MGUS)
(1)
Glioblastoma multiforme
(1)
Neoplasm Metastasis
(1)
Alveolar rhabdomyosarcoma
(1)
B-cell lymphoma
(1)
Breast cancinoma
(1)
Burkitt lymphoma
(1)
COVID-19
(1)
Cell type cancer
(1)
Cutaneous malignant melanoma 1
(1)
Embryonal rhabdomyosarcoma
(1)
Technology Type
Mass Spectrometry
(126)
Shotgun proteomics
(50)
Affinity purification coupled with mass spectrometry proteomics
(29)
Bottom-up proteomics
(26)
Data-dependent acquisition
(19)
Mass spectrometry assay
(16)
Mass spectrometry
(12)
Top-down proteomics
(7)
Data-independent acquisition
(6)
Illumina HiSeq 2500, ILLUMINA
(5)
SWATH MS
(5)
Immunopeptidomics
(4)
SRM/MRM
(3)
Gel-based experiment
(2)
Illumina HiSeq 2500 (ILLUMINA), Illumina HiSeq 4000 (ILLUMINA)
(1)
Illumina HiSeq 4000, Illumina HiSeq 2500, ILLUMINA
(1)
Illumina
(1)
NMR spectroscopy assay
(1)
NMR spectroscopy
(1)
Instrument Platform
Illumina NovaSeq 6000
(19)
Orbitrap Fusion Lumos
(13)
NextSeq 500
(7)
Orbitrap Fusion
(6)
Q Exactive
(6)
Illumina HiSeq 4000
(5)
Q Exactive Plus
(5)
Illumina HiSeq 2500
(4)
LTQ Orbitrap
(3)
LTQ Orbitrap Elite
(3)
Orbitrap Eclipse
(3)
Orbitrap Exploris 480
(3)
Illumina NovaSeq X
(2)
NextSeq 2000
(2)
Illumina MiSeq
(2)
Illumina HiSeq 2000
(2)
Q Exactive HF
(2)
TimsTOF Pro 2
(2)
NCounter Pro and nCounter Pro Analysis System
(1)
10x genomic Chromium controller
(1)
Agilent Technologies Scanner G2505C
(1)
NextSeq 1000
(1)
NA
(1)
DNBSEQ-G400
(1)
NextSeq 550
(1)
Ion S5XL
(1)
-
(1)
6495C Triple Quadrupole LC/MS
(1)
6546 Q-TOF LC/MS (Agilent Instrument model)
(1)
Q Exactive HF-X
(1)
Publication Date
2025
(212)
2026
(183)
2024
(164)
2023
(154)
2022
(105)
2021
(81)
2020
(54)
2015
(37)
2019
(31)
2016
(28)
2018
(25)
2014
(23)
2013
(17)
2010
(16)
2017
(14)
2012
(13)
2011
(11)
2008
(9)
2009
(5)
2007
(3)
2005
(3)
2006
(2)
UNIPROT ID/AC
Q49IL8
(1)
B5MCZ3
(1)
Q14609
(1)
P22301
(1)
P60568
(1)
P01137
(1)
CHEBI ID
CHEBI:16761
(5)
CHEBI:16708
(4)
CHEBI:16027
(4)
CHEBI:25017
(3)
CHEBI:15422
(3)
CHEBI:17368
(3)
CHEBI:30769
(3)
CHEBI:17768
(2)
CHEBI:24266
(2)
CHEBI:17033
(2)
CHEBI:16264
(2)
CHEBI:16709
(2)
CHEBI:26271
(2)
CHEBI:25094
(2)
CHEBI:22653
(2)
CHEBI:48928
(2)
CHEBI:16811
(2)
CHEBI:17562
(2)
CHEBI:16750
(2)
CHEBI:17748
(2)
CHEBI:15741
(2)
CHEBI:6650
(2)
CHEBI:17154
(2)
CHEBI:37024
(2)
CHEBI:52392
(2)
CHEBI:116314
(2)
CHEBI:16393
(2)
CHEBI:35581
(2)
CHEBI:16235
(2)
CHEBI:16335
(2)
Metabolite Name
Creatinine
(5)
D-Ornithine
(4)
Uracil
(4)
Betaine
(4)
Thymine
(4)
Pyroglutamic acid
(4)
Gluconic acid
(4)
Xanthosine
(4)
Citric acid
(4)
Adenosine
(4)
Spermidine
(4)
L-Tryptophan
(4)
Glucose
(4)
Xanthine
(4)
Sucrose
(4)
Creatine
(4)
1-Methyladenosine
(4)
Hypoxanthine
(4)
N-Formylglycine
(3)
Fucose 1-phosphate
(3)
Juglone
(3)
Thiamine monophosphate
(3)
Galactaric acid
(3)
N-Acetylasparagine
(3)
Galacturonic acid
(3)
S-Lactoylglutathione
(3)
2'-Deoxyadenosine
(3)
N-Methyl-D-aspartic acid
(3)
L-Cystine
(3)
Norvaline
(3)
First Public Date
2025
(183)
2026
(179)
2023
(136)
2024
(131)
2022
(89)
2021
(79)
2020
(42)
2019
(27)
2018
(12)
2017
(11)
2016
(8)
2015
(6)
2014
(6)
2013
(2)
Modelling Approach
Ordinary differential equation model
(14)
Study status
Terminated
(2)
Not provided
(2)
Completed
(2)
Active, not recruiting
(1)
Not yet recruiting
(1)
Recruiting
(1)
Lab affiliation
Drug Discovery Moffitt Cancer Center Tampa, FL, USA
(4)
Department of Chemical & Systems Biology, Stanford University, USA
(3)
Department of Pathology, Dalhousie University
(3)
Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Office B25A/04/94 Rue du Bugnon 25a, CH-1005 Lausanne
(3)
Tumor Biology Department Molecular Medicine Program Moffitt Cancer Center Tampa, FL, USA
(3)
Cellular Neurophysiology, Center for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, 66421 Homburg, Germany
(2)
Center for Immunity and Immunotherapies, Seattle Children's Research Institute. Department of Pediatrics, University of Washington. Seattle, WA USA
(2)
Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
(2)
Charité-University Medicine Berlin
(2)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
(2)
ETH Zurich Institute of Molecular Systems Biology
(2)
Immunology Unit, Department of Cell Biology, Physiology and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra (Cerdanyola del Vallès), Spain Biosensing and Bioanalysis Group, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra (Cerdanyola del Vallès), Spain
(2)
Massachusetts Institute of Technology
(2)
Monash University
(2)
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
(2)
1 Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn. 2 Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD)
(1)
1. Monash Proteomics and Metabolomics Facility, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia 2. School of Clinical Sciences, Department of Medicine, Monash University, Clayton, Victoria, Australia
(1)
1CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada 2 Department of Pathology and cellular biology, Faculty of Medicine, Universite de Montreal, QC H3T 1J4, Canada
(1)
Academy Professor, Turku Centre for Biotechnology, University of Turku and Abo Akademi University, Turku, Finland
(1)
Associate Professor, Department of Laboratory Medicine, UCSF
(1)
BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC UMR 7178, University of Strasbourg, CNRS
(1)
Bioanalytical Research Labs, Department of Biosciences & Medical Biology, Universität Salzburg, Austria
(1)
Boston University
(1)
BriaCell Therapeutics Corporation, Berkeley, CA, USA
(1)
Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA USA
(1)
Center for Regeneration and Aging,BGI-haangzhou
(1)
Center of experimental therapeutics Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Centre de recherche Agora Rue du Bugnon 25A CH-1005 Lausanne
(1)
Chancellor's Professor of Bioengineering University of California Los Angeles
(1)
Children's Hospital of Philadelphia
(1)
Clinical Research Division, Fred Hutchinson Cancer Center, USA
(1)
Tags
xref:PubMed:40730154
(8)
xref:PubMed:35311997
(6)
xref:PubMed:40023154
(6)
xref:PubMed:37714135
(6)
xref:PubMed:37142692
(6)
xref:PubMed:41747251
(6)
xref:PubMed:42556334
(5)
xref:PubMed:39983725
(5)
xref:PubMed:37086018
(5)
xref:PubMed:39604727
(5)
xref:PubMed:37040762
(4)
xref:PubMed:35113687
(4)
xref:PubMed:37454216
(4)
xref:PubMed:37407815
(4)
xref:PubMed:36111282
(4)
xref:PubMed:37418548
(4)
xref:PubMed:39701099
(4)
xref:PubMed:41747043
(4)
xref:PubMed:36038492
(4)
xref:PubMed:42760560
(4)
xref:PubMed:40050704
(4)
xref:PubMed:39642889
(4)
xref:PubMed:31011226
(3)
xref:PubMed:39145444
(3)
xref:PubMed:41081756
(3)
xref:PubMed:36423635
(3)
xref:PubMed:39578450
(3)
xref:PubMed:33046887
(3)
xref:PubMed:37069398
(3)
xref:PubMed:37653344
(3)
Keyword
Pembrolizumab
(4)
Immunotherapy
(4)
Nivolumab
(2)
Avelumab
(2)
Interleukin-15
(1)
PD-1 Checkpoint Inhibitor
(1)
ALT-803
(1)
Small Cell Lung Cancer (SCLC)
(1)
Head and Neck Squamous Cell Carcinoma (HNSCC)
(1)
Merkel Cell Carcinoma (MCC)
(1)
Renal Cell Carcinoma (RCC)
(1)
Hepatocellular Carcinoma (HCC)
(1)
Microsatellite Instability-High (MSI-H)
(1)
PD-L1 Checkpoint Inhibitor
(1)
Mismatch Repair Deficient (dMMR) Solid Tumor Cancer
(1)
PD-L1 t-haNK
(1)
Imfinzi
(1)
Bavencio
(1)
Tecentriq
(1)
NOX-A12
(1)
Olaptesed pegol
(1)
Spiegelmer
(1)
Stromal cell-derived factor-1 (SDF-1)
(1)
CXCL12
(1)
Checkpoint inhibition
(1)
PD-1 inhibitor
(1)
Checkpoint inhibitor
(1)
H-MSI
(1)
Keytruda
(1)
Anti-MCSF
(1)
IsPrivate
False
(14)
Submitter Keywords
Immuno-oncology
(12)
Classification
protozoa
(1)
Study type
Transcription profiling by array
(129)
RNA-seq of coding RNA
(32)
RNA-seq of coding RNA from single cells
(20)
Interventional
(7)
MicroRNA profiling by array
(3)
Proteomic profiling by array
(3)
Unknown experiment type
(2)
Human - One-color microarray
(2)
Genotyping by array
(2)
DNA-seq
(2)
Methylation profiling by array
(2)
RNA-seq of total RNA
(2)
Observational
(2)
Human - High-throughput sequencing
(1)
Animal - High-throughput sequencing
(1)
Transcription profiling by RT-PCR
(1)
MicroRNA profiling by high throughput sequencing
(1)
Comparative genomic hybridization by array
(1)
Release Date
2022
(989)
2023
(979)
2021
(972)
2025
(810)
2024
(702)
2020
(696)
2019
(451)
2018
(352)
2017
(281)
2016
(238)
2015
(158)
2014
(134)
2026
(113)
2013
(75)
2012
(62)
2011
(43)
2010
(36)
2009
(15)
2008
(15)
2005
(7)
2007
(4)
2003
(3)
2006
(2)
2004
(1)
2002
(1)
2000
(1)
1999
(1)
Location
Germany
(4)
United States
(3)
Italy
(2)
Australia
(2)
Taiwan
(1)
Poland
(1)
Spain
(1)
Belgium
(1)
Canada
(1)
Netherlands
(1)
United Kingdom
(1)
Japan
(1)
France
(1)
Previous
page
1 / 921
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
921
Next
page
Sort
by:
Relevance
Page size
10
Novel Immunotherapies for T Cell Lymphoma and Leukemia.
Not available
S-EPMC6295363
|
biostudies-literature
Cite
A phase I trial of cyclosporine for hospitalized patients with COVID-19.
Not available
S-EPMC9220832
|
biostudies-literature
Cite
Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
PRJNA1107960
|
ENA
Cite
Cellular immunotherapies for cancer.
Not available
S-EPMC7326625
|
biostudies-literature
Cite
Engineered cellular immunotherapies in cancer and beyond.
Not available
S-EPMC9305718
|
biostudies-literature
Cite
Repurposing CD19-directed immunotherapies for pediatric t(8 21) acute myeloid leukemia
Repurposing CD19-directed immunotherapies for pediatric t(8 21) acute myeloid leukemia
PRJNA1125391
|
ENA
Cite
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.
Not available
S-EPMC7640763
|
biostudies-literature
Cite
Inhibition of PARP11 inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies.
Inhibition of PARP11 inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies.
PRJNA1048463
|
ENA
Cite
Immunotherapies for Neurodegenerative Diseases.
Not available
S-EPMC8215715
|
biostudies-literature
Cite
Immunotherapies and Combination Strategies for Immuno-Oncology.
Not available
S-EPMC7404041
|
biostudies-literature
Cite
Previous
page
1 / 921
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
921
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets